The short version of nuclear receptor fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-09-14. Anything still debated is marked as such rather than presented as settled.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ in preclinical models |
| Molecular formula | C20H24ClN3O4S | Reported for the parent compound |
| CAS Registry Number | 1379686-30-2 | Common identifier in chemical databases |
| Appearance | Off-white to pale yellow solid | Typical research chemical solid |
| Solubility | Soluble in DMSO and ethanol; low in water | Class: small organic molecule |
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
=== Personal objections === Sometimes people refuse blood transfusions because of fears about the safety of the blood supply. Generally speaking, the rules of informed consent allow mentally competent adults to refuse blood transfusions even when their objections are based on misinformation or prejudice and even when their refusal may result in serious and permanent harm, including death. For example, since COVID-19 vaccines became available, some people have refused blood transfusions because the donor might have been vaccinated, and they fear that this would cause secondhand harm to them. This choice is based on false beliefs, but a mentally competent adult's choices are normally respected. However, if doctor's opinions are that parents and guardians are making harmful choices about children, they can be overruled (in some jurisdictions) using legal arguments based on the harm principle; in this case if doctors believe that refusing the blood transfusion would put the child at risk of serious injury or death. Blood banks do not collect information that is irrelevant to the transfusion process, including the donors' race, ethnicity, sexual orientation, COVID-19 vaccination status, etc., so selecting blood units based on the individual's personal objections is not practical.
cell counting The process of determining the number of cells within a biological sample or culture by any of a variety of methods. Counting cells is an important aspect of cytometry used widely in research and clinical medicine. It is generally achieved by using a manual or digital cytometer to count the number of cells present in small fractions of a sample, and then extrapolating to estimate the total number present in the entire sample. The resulting quantification is typically expressed as a density or concentration, i.e. the number of cells per unit area or volume.
=== Randomness of mutations === There is a widespread assumption that mutations are (entirely) "random" with respect to their consequences (in terms of probability). This was shown to be wrong as mutation frequency can vary across regions of the genome, with such DNA repair- and mutation-biases being associated with various factors. For instance, Monroe and colleagues demonstrated that—in the studied plant (Arabidopsis thaliana)—more important genes mutate less frequently than less important ones. They demonstrated that mutation is "non-random in a way that benefits the plant". Additionally, previous experiments typically used to demonstrate mutations being random with respect to fitness (such as the Fluctuation Test and Replica plating) have been shown to only support the weaker claim that those mutations are random with respect to external selective constraints, not fitness as a whole.
== E == Electrodialysis Electrolysis Electron microscopy Electron paramagnetic resonance (EPR) also called Electron spin resonance (ESR) Electrophoresis Energy Dispersive Spectroscopy (EDS/EDX) Electron diffraction (ED)
Sources: en.wikipedia.org
== Use and effects == In his book TiHKAL (Tryptamines I Have Known and Loved), Alexander Shulgin lists the dose range of 4-HO-MET as 10 to 20 mg orally and its duration as 4 to 6 hours. However, a wider recreational dose range of 2 to 45 mg or more orally, with a typical dose estimate of 15 mg, has also been reported. The drug's onset is said to be within 30 minutes. The effects of 4-HO-MET have been reported to include pupil dilation, euphoria, tingling sensations, perceptual changes, closed- and open-eye visuals, synesthesia, time dilation, intensified perceptions, thoughts, and feelings, and a general change in thought processes. Other specific effects include alteration of color and form, feeling sounds, and a wave-like experience with alternation between near-normal perception one moment and a "swirl of altered concept" the next moment. 4-HO-MET is said to produce qualitative effects very similar to those of psilocin. Shulgin has stated that he doubts it could be distinguished from psilocin in any blinded clinical study. However, the drug has also been described as being relatively or very light, more clear-headed and functional, and having less head space. On the other hand, it is said to still produce strong psychedelic visuals. This profile of effects has been described as being analogous to the case of 2C-B. In addition to its use on its own, 4-HO-MET, along with the related tryptamine psychedelic 5-MeO-MiPT, is employed at low doses as a component of the MDMA-mimicking Borax combo.
== Post-parliamentary career (2024–present) == In June 2025, Galloway renounced his opposition to Scottish independence, saying that he would now be in favour of a second referendum. Writing on X, he said: “We support the right of the Scots to self-determination. Eleven years after they last did so we believe the time for another referendum is close. Given the collapsing authority of the British state, the pitiful prime minister Starmer and the moral decline of British society, the result cannot easily be predicted. Britain has become a cesspit." This followed a comment Galloway had made on X in September 2024, in which he said: "You COULD persuade me to Scottish Independence, you could never persuade me to the SNP." In August 2025, Galloway announced that he would be contesting the 2026 Scottish Parliament election as the Workers Party candidate for Glasgow Southside. Additionally, he said that he would be second on the party list for the Glasgow region. In a press conference shortly after his election as MP for Rochdale in February 2024, Galloway had said that he was "no longer involved in Scottish politics", though did mention his support of the SNP's stance on Gaza, adding that they had been “outstanding on the Gaza question, at least by comparison with the two big parties of the state”. In light of this, he revealed that friend and lead candidate for Glasgow, Yvonne Ridley, had persuaded him to stand.
In 2005, Katja Seipel and Volker Schmid suggested that cnidarians and ctenophores are simplified descendants of triploblastic animals, since ctenophores and the medusa stage of some cnidarians have striated muscle, which in bilaterians arises from the mesoderm. They did not commit themselves on whether bilaterians evolved from early cnidarians or from the hypothesized triploblastic ancestors of cnidarians. Resolving the evolutionary relationships within Cnidaria has also been challenging, with almost every possible combination of clades being proposed. As time went on though, a semi-consensus has started to emerge. The enigmatic Polypodium hydriforme and subphylum Myxozoa have been firmly placed within the Cnidaria and have been shown to be closely related to the Medusozoa. In addition, these two groups have been found to likely be each other's closest relatives which, if true, would form the clade "Endocnidozoa". The relationships within the Medusozoa are currently probably the most contentious part of the tree. Traditionally, the class Scyphozoa also included Staurozoa and Cubozoa, but significant morphological differences eventually lead to the split of the three. The group containing them has since been named "Acraspeda". The relationships between these three and Hydrozoa have since and still are debated. A relationship between Scyphozoa and Cubozoa with Staurozoa as its sister has seen support in nearly all studies, but the position of the remaining class, Hydrozoa, is not understood.
Sources: en.wikipedia.org
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.
No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.
Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.
Research-grade SR9009 is typically stored frozen at about minus twenty degrees Celsius, protected from light and moisture. Stock solutions are often kept in aliquots to avoid repeated freeze-thaw cycles. Specific storage conditions should follow the supplier's documentation.